Reports


Antiviral Drugs Treatment Market by Drug Class (DNA polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), by Type (Branded, and Generic), and Application (HIV, Hepatitis, Herpes, Influenza, and Others) – Global Industry Analytics COVID-19 Business Impact, and Trends, 2020-2026

  • TBI900516
  • July 24, 2020
  • Global
  • 132 pages
  • SAC Insights
                                              Abstract
                    
The report covers forecast and analysis for the Antiviral Drugs Treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the Antiviral Drugs Treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Antiviral Drugs Treatment market on a global level. In order to give the users of this report a comprehensive view on the Antiviral Drugs Treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Drug Class, Type, Application, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Viral infections have caused millions of human casualties worldwide across human history, prompting the production of antiviral drugs in urgent need. A new period of antiviral drug production began in June 1963, when the first antiviral medication, idoxuridine, was approved. Antiviral drugs pertain to the class of medicines that have been used to treat viral infections including HIV, measles, hepatitis, and influenza. In general such medications are distributed in the form of vaccines. Moreover, most of these medications are used for common viral infections, while some (full-spectrum antiviral drugs) are effective against a large range of viruses.


The study provides a decisive view on the Antiviral Drugs Treatment market by segmenting the market based on Drug Class, Type, Application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. Based on Drug Class, the market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others.

Based on Type, the market is segmented into Branded, and Generic. Based on Application, the market is segmented into HIV, Hepatitis, Herpes, Influenza, and Others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically speaking, North America dominated the Antiviral Drugs Treatment market with a share of about 37.22% in 2019. The key players’ presence in the region, convenience of refined healthcare infrastructure, and cumulative awareness of viral diseases has led to increased demand for Antiviral drugs in North America region.

Growing occurrence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza is projected to boost the demand for antiviral drugs. Hepatitis B, for example, has caused about 987,000 deaths in 2017 according to data released by the WHO. In addition, in 2017 about 287 million patients were reported to have been infected with hepatitis B virus (HBV) infection. This is expected to drive the demand for efficient treatment solutions such as antiviral drugs.

Key players within global Antiviral Drugs Treatment market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. & Co., Inc and others.

The report segments global Antiviral Drugs Treatment market as follows:

Global Antiviral Drugs Treatment Market: Drug Class Segment Analysis

	DNA Polymerase Inhibitors
	Reverse Transcriptase Inhibitors
	Protease Inhibitors
	Neuraminidase Inhibitors
	Others

Global Antiviral Drugs Treatment Market: Type Segment Analysis

	Branded
	Generic

Global Antiviral Drugs Treatment Market: Application Segment Analysis

	HIV
	Hepatitis
	Herpes
	Influenza
	Others

Global Antiviral Drugs Treatment Market: Regional Segment Analysis

	North America
	
		The U.S.
		Canada
	
	
	Europe
	
		France
		The UK
		Spain
		Germany
		Italy
		Rest of Europe
	
	
	Asia Pacific
	
		China
		Japan
		India
		South Korea
		Southeast Asia
		Rest of Asia Pacific
	
	
	Latin America
	
		Brazil
		Mexico
		Rest of Latin America
	
	
	Middle East & Africa
	
		GCC
		South Africa
		Rest of Middle East & Africa 

Table of Contents
                    
                    
                         Request Table Of Content
                         Click To Request Sample
                    

	Chapter 1. Preface
	
		1.1. Report Description and Scope
		1.2. Research Scope
		1.3. Research Methodulogy
		
			1.3.1. Market Research Process
			1.3.2. Market Research Methodulogy
		
		
	
	
	Chapter 2. Executive Summary
	
		2.1. Antiviral Drugs Treatment Market, 2016 - 2026, (USD Billion)
		2.2. Antiviral Drugs Treatment Market: Snapshot
	
	
	Chapter 3. Global Ant
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form